Cross-Linking of DNA by Alkylating Agents and Effects on DNA Function in the Chick Embryo

Total Page:16

File Type:pdf, Size:1020Kb

Cross-Linking of DNA by Alkylating Agents and Effects on DNA Function in the Chick Embryo (CANCER RESEARCH 31, 1573-1579, November 1971] Cross-linking of DNA by Alkylating Agents and Effects on DNA Function in the Chick Embryo Jerome J. McCann, Timothy M. Lo, and D. A. Webster Department of Biology, Illinois Institute of Technology, Chicago, Illinois 60616 SUMMARY single-stranded DNA partitions into the dextran-rich lower phase (3). This assay has been used to demonstrate that many Drug-induced cross-links are found in the DNA of chick preparations of DNA normally contain some cross-linked embryos within 6 hr after injection of mitomycin C and DNA, which was postulated to arise when DNA is sheared methyl-di-(2-chloroethyl)amine into the egg and 24 hr after during purification (2, 3). In Escherichia coli, an enzyme injection of triethylene thiophosphoramide. Effects on the system, consisting of an exonuclease and a ligase, has been rates of synthesis of DNA, RNA, and protein were studied shown to cross-link DNA terminally (25). with chemical assays for total content of these When difunctional alkylating agents were injected onto the macromolecules as well as radioactive precursor incorporation. area vasculosa of 4-day chick embryos in ovo, within 24 hr a All three drugs inhibited DNA synthesis before RNA and specific type of macrophage was formed over the entire protein synthesis were affected, but there were discrepancies embryo (24). These macrophages were indistinguishable by between the two methods of measuring macromolecular light and electron microscopy from macrophages which are synthesis; thus, radioactive precursor incorporation is not formed during the process of "programmed cell death," a always a reliable measurement of macromolecular synthesis in phenomenon believed important for sculpturing the normal the chick embryo. When the effects of contours of the limbs (18). The macrophages arise from methyl-di-(2-chloroethyl)amine were compared to those of mesodermal cells adjacent to the dead or dying cells, dimethyl-2-chloroethylamine, a monofunctional analog, the presumably in response to their moribund state, and engulf former was a more effective inhibitor of DNA and RNA and digest the cells and cell debris associated with cell death synthesis at equivalent alkylating doses; however, the fact that (18). Besides the difunctional alkylating agents, only the monofunctional analog had some inhibitory activity hydroxyurea and daunomycin could induce the formation of suggests that not all the effects of difunctional alkylating macrophages in 4- and 5-day chick embryos; all other tested agents are due to their DNA cross-linking activity. metabolic poisons did not have this effect. The latter included monofunctional alkylating agents, actinomycin D, cycloheximide, colchicine, cyanide, and many others (24). On INTRODUCTION the basis of these results, it was postulated that programmed cell death may occur by a mechanism similar to that produced Alkylating agents are inhibitors of cell division, and for this by the difunctional alkylating agents, hydroxyurea, and reason they have been valuable tools for both basic research in daunomycin. With the polyethylene glycol-dextran 2-phase cell biology and cancer chemotherapy. It had been speculated system, DNA from chick embryos treated with mitomycin C, that the difunctional (and polyfunctional) alkylating agents thioTEPA,1 or Carzinophilin was demonstrated to contain a exerted their effects because of their ability to cross-link DNA. higher percentage of cross-linked DNA than untreated Although there was evidence for the ability of these agents to embryos, but DNA from chick embryo tissues containing cross-link DNA in vitro (4, 8, 12, 15), no such evidence fora prospective necrotic cells and necrotic cells contained no similar activity in vivo was available until Szybalski and Iyer higher percentage of cross-linked DNA than control tissues (21) using cesium salt density gradient centrifugation showed (24). Although these direct experiments failed to demonstrate that mitomycin C in the growth medium cross-linked the DNA a role for cross-linked DNA in programmed cell death, they are of bacterial cells and mammalian tissue culture cells. They also inconclusive because of the relatively few cells involved, the demonstrated that the amount of cross-linking increased with fact that they comprised only about 1% of the extirpated increasing amounts of mitomycin C in the medium. tissues, and limitations of the assay, which would have Cross-linked DNA, when denatured, will spontaneously required about 700 more cross-links per nucleus to have "zipper up" to reform double-stranded helical DNA; this detected an increase in cross-linked DNA (24). The positive process is concentration independent, and one needs only to effects of hydroxyurea, a specific inhibitor of DNA synthesis be able to detect a small fraction of double-stranded DNA in (13), and daunomycin, which also affects nucleic acid the presence of a large amount of single-stranded DNA. A new metabolism although the mechanism of its action is not known assay, which can do this, uses polyethylene glycol and dextran (11), suggest that an inhibition of DNA synthesis is the in a 2-phase system in which double-stranded DNA partitions into the polyethylene glycol-rich upper phase and 'The abbreviations used are: thioTEPA, triethylene thiophos Received April 8, 1971 ¡acceptedJune 15, 1971. phoramide; HN2, methyl-di-(2-chloroethyl)amine. NOVEMBER 1971 1573 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 1971 American Association for Cancer Research. Jerome J. McCann, Timothy M. Lo, and D. A. Webster primary mechanism by which all these drugs act and may also RNA with the orcinol assay (19), and protein with thebiuret be a primary mechanism of cell death in programmed cell assay. death during normal chick embryo development. Thus, it For the estimation of cross-linked DNA, the embryos were became imperative to study the effect of these drugs on homogenized in 0.15 M NaCl : 0.1 M EDTA, pH 8.1, 2 macromolecular synthesis, especially DNA synthesis, during ml/embryo, with a glass homogenizer fitted with a Teflon chick embryo development. First, we undertook a detailed pestle. Pronase (Calbiochem, Los Angeles, Calif.), and a 20% study of the cross-linking activity of various drugs with the solution of sodium dodecyl sulfate were added to give final polyethylene glycol-dextran 2-phase system but with an concentrations of 500 ng/ml and 1%, respectively. After incubation for 20 to 24 hr at 37°, the solutions were abridged procedure relative to that used formerly (24). The drugs tested were mitomycin C, HN2, thioTEPA, deproteinized with an equal volume of chloroformibutanol hydroxyurea, and dimethyl-2-chloroethylamine. The effects of (4:1, v/v) and centrifuged to separate the phases, and the these drugs on the incorporation of specific radioactive nucleic acids were precipitated from the aqueous phase with precursors into DNA, RNA, and protein as a function of time 95% ethanol. The nucleic acids were collected on a stirring rod after injection was determined as well as their effects on total and dissolved in cold 0.2 M NaOH:0.02 M EDTA (trisodium salt). The solutions were warmed to 45°for 15 min, cooled to DNA, RNA, and protein content. The results show that difunctional alkylating agents can cross-link the DNA of the 0°,and neutralized with 0.3 volume of 1.0 M KH2P04. After chick embryos within 6 hr after their injection and that DNA another deproteinization step with chlorofornrbutanol, the is the first macromolecule for which synthesis is inhibited by solutions were dialyzed against 1 liter of 0.01 M sodium these drugs. phosphate, pH 7.0, for ca. 24 hr at 4°with 1 change of buffer. Chloroform was added to the dialysis buffer, and the dialysis MATERIALS AND METHODS tubing was boiled for 30 min in 0.1 M acetic acid to remove UV-absorbing materials. Cross-linked DNA content of the The drugs were obtained from the same sources that were dialyzed samples was estimated with the polyethylene used previously (24). The radioactive compounds were glycol:dextran 2-phase system (1) with a stock made up of purchased from International Chemical and Nuclear Corp., 23% (w/w) polyethylene glycol and 3 volumes 34% (w/w) Irvine, Calif., and had the following specific activities: dextran. One volume of sample was added to 0.8 volume of thymidine-methyl-3H (10.5 Ci/mmole), uridine-5-3H (21.7 stock solution and mixed intermittently with a Vortex mixer Ci/mmole), L-leucine-4,5-3H (29.8 Ci/mmole), uridine-2-14C for 1 to 2 hr. Low-speed centrifugation separated the phases, (30 mCi/mmole), L-leucine-14C (uniformly labeled, 210 and the upper phase containing the double-stranded DNA was mCi/mmole). The fertile eggs were obtained from C. L. Sharp carefully removed and mixed with an approximately equal (Glen Ellyn, 111.). DNase 1 (bovine pancreas) and RNase volume of chloroform to precipitate the phase polymers. After (bovine pancreas) were purchased from Worthington Bio centrifugation, the upper aqueous phase was removed and chemical Corp. (Freehold, N.J.). We used Pharmacia T500 assayed directly for DNA content with the Burton dextran, Lot 4024, primarily, and General Biochemicals, Inc. modification (6) of the diphenylamine assay except that the (Chagrin Falls, Ohio) polyethylene glycol (M.W.5700 to precipitation step was omitted. The DNA content of the 6700), Lot 88452. dialyzed samples before phase separation was simultaneously Eggs were incubated for 4 days and candled to determine determined; all determinations were in duplicate. Appropriate the position of the embryo, and the drugs were injected on the controls were run simultaneously in the 2-phase system, area vasculosa as previously described (24). The radioactive including native DNA, heat-denatured DNA, and phosphate precursors were injected into the yolk sac through a hole buffer alone. drilled in the narrow end of the egg.
Recommended publications
  • Induction with Mitomycin C, Doxorubicin, Cisplatin And
    British Journal of Cancer (1999) 80(12), 1962–1967 © 1999 Cancer Research Campaign Article no. bjoc.1999.0627 Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study RL Hong1, TS Sheen2, JY Ko2, MM Hsu2, CC Wang1 and LL Ting3 Departments of 1Oncology, 2Otolaryngology and 3Radiation Therapy, National Taiwan University Hospital, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 10016, Taiwan Summary The combination of cisplatin and 5-fluorouracil (5-FU) (PF) is the most popular regimen for treating metastatic nasopharyngeal carcinoma (NPC) but it is limited by severe stomatitis and chronic cisplatin-related toxicity. A novel approach including induction with mitomycin C, doxorubicin and cisplatin (MAP) and subsequent maintenance with weekly 5-FU and leucovorin (FL) were designed with an aim to reduce acute and chronic toxicity of PF. Thirty-two patients of NPC with measurable metastatic lesions in the liver or lung were entered into this phase II trial. Mitomycin C 8 mg m–2, doxorubicin 40 mg m–2 and cisplatin 60 mg m–2 were given on day 1 every 3 weeks as initial induction. After either four courses or remission was achieved, patients received weekly dose of 5-FU 450 mg m–2 and leucovorin 30 mg m–2 for maintenance until disease progression. With 105 courses of MAP given, 5% were accompanied by grade 3 and 0% were accompanied by grade 4 stomatitis. The dose-limiting toxicity of MAP was myelosuppression. Forty per cent of courses had grade 3 and 13% of courses had grade 4 leukopenia.
    [Show full text]
  • The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism.
    [Show full text]
  • The Synergistic Anti-Neoplastic Activity of Combinations of Mitomycins with Either 6-Thioguanine Or @.-F1uorouracip
    CANCER RESEARCH VOLUME 25 OCTOBER 1965 NUMBER 9 The Synergistic Anti-neoplastic Activity of Combinations of Mitomycins with Either 6-Thioguanine or @.-F1uorouraciP ALAN C. SARTORELLI AND BARBARA A. BOOTH Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut SUMI@1ARY Mitomycin C or porfiromycin (methyl mitomycin) in combination with either 6- thioguanine or 5-fluorouracil produced synergistic inhibition of the growth of both Sar coma 180 and Lymphoma L1210 ascites cell neoplasms. i\Iitomycin C and porfiromy cm possessed the same therapeutic index in the L1210 lymphoma system, but mitomycin C was about 5 times more potent. Doses of mitomycin C that induced pro nounced inhibition of thymidine-3H incorporation into deoxyribonucleic acid (DNA) did not decrease the average DNA content of treated cells. The degree of inhibition of ribonucleic acid (RNA) synthesis by mitomycin C was less pronounced than that of DNA, and lysine-1-'4C fixation into residual protein was insensitive to the antibiotic. 6-Thioguanine induced a marked depression in the rate of incorporation of thymidine 3H and orotic acid-6-'4C into DNA and RNA, respectively. The combination of these agents produced subadditive to additive inhibition of the formation of nucleic acids and also caused inhibition of protein synthesis; incorporation of thymidine into DNA ap peared to be the metabolic path most sensitive to the combination of these agents. Measurement of thymidine kinase and thymidylate kinase activity in cells treated with these agents indicated that these enzymes were relatively resistant to the action of mi tomycin C ; however, some inhibition of thymidylate kinase activity was induced by the thioguanine treatment.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,921,361 B2 Cmiljanovic Et Al
    USOO892.1361 B2 (12) United States Patent (10) Patent No.: US 8,921,361 B2 Cmiljanovic et al. (45) Date of Patent: Dec. 30, 2014 (54) TRIAZINE, PYRIMIDINE AND PYRIDINE 409/04 (2013.01); C07D 413/04 (2013.01); ANALOGS AND THEIR USEAS C07D 413/14 (2013.01); C07D 417/04 THERAPEUTICAGENTS AND DAGNOSTIC (2013.01); C07D 417/14 (2013.01); C07D PROBES 491/048 (2013.01); C07D491/147 (2013.01); C07D 495/04 (2013.01); C07D 495/14 (2013.01); C07D498/04 (2013.01); C07D (75) Inventors: Vladimir Cmiljanovic, Basel (CH): 513/04 (2013.01); C07D 519/00 (2013.01) Natasa Cmiljanovic, Basel (CH); Bernd USPC .......................................... 514/232.2:544/83 Giese, Fribourg (CH); Matthias (58) Field of Classification Search Wymann, Bern (CH) None See application file for complete search history. (73) Assignee: University of Basel, Basel (CH) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 60 days. 5,489,591 A * 2/1996 Kobayashi et al. ........... 514,245 (21) Appl. No.: 13/128,436 7,173,029 B2 2/2007 Hayakawa et al. 8,217,036 B2 * 7/2012 Venkatesan et al. ....... 514,232.2 (22) PCT Filed: Nov. 10, 2009 2010 OO69629 A1 3/2010 Shimma et al. (86). PCT No.: PCT/B2O09/OOT404 FOREIGN PATENT DOCUMENTS EP 1864 665 A1 12/2007 S371 (c)(1), WO 2005/028444 A1 3, 2005 (2), (4) Date: Jul. 1, 2011 WO 2007 1271.75 A2 11/2007 WO 2008/O18426 A1 2, 2008 (87) PCT Pub.
    [Show full text]
  • Interactions of Antitumor Triazoloacridinones with DNA
    Vol. 54 No. 2/2007, 297–306 on-line at: www.actabp.pl Regular paper Interactions of antitumor triazoloacridinones with DNA * Marcin Koba and Jerzy Konopa Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland Received: 12 February, 2007; revised: 20 March, 2007; accepted: 21 March, 2007 available on-line: 19 April, 2007 Triazoloacridinones (TA) are a new group of potent antitumor compounds, from which the most active derivative, C-1305, has been selected for extended preclinical trials. This study investi- gated the mechanism of TA binding to DNA. Initially, for selected six TA derivatives differing in chemical structures as well as cytotoxicity and antitumor activity, the capability of noncova- lent DNA binding was analyzed. We showed that all triazoloacridinones studied stabilized the DNA duplex at a low-concentration buffer but not at a salt concentration corresponding to that in cells. DNA viscometric studies suggested that intercalation to DNA did not play a major role in the mechanism of the cytotoxic action of TA. Studies involving cultured cells revealed that triazoloacridinone C-1305 after previous metabolic activation induced the formation of interstrand crosslinks in DNA of some tumor and fibroblast cells in a dose dependent manner. However, the detection of crosslink formation was possible only when the activity of topoisomerase II in cells was lowered. Furthermore, it was impossible to validate the relevance of the ability to crosslink DNA to biological activity of TA derivatives. Keywords: triazoloacridinones, DNA intercalation, DNA interstrand crosslinks, structure–activity relationship, biological activity, metabolic activation INTRODUCTION Previous investigations demonstrated that triazoloacridinones inhibited cleavable complexes of Triazoloacridinones (TA) (see Table 1, for topoisomerase II–DNA and also the catalytic activity structures) are a class of antitumor agents synthe- of this enzyme (Skladanowski et al., 1999; Lemke et sized in our laboratory (Cholody et al., 1990).
    [Show full text]
  • Characterization of SPRTN, the First Mammalian Metalloprotease That Repairs DNA-Protein-Crosslinks
    Aus dem Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt am Main betreut am Gustav Embden-Zentrum der Biochemie Institut für Biochemie II (Kardiovaskuläre Biochemie) Direktor: Prof. Dr. Ivan Dikic Characterization of SPRTN, the first mammalian metalloprotease that repairs DNA-protein-crosslinks Dissertation zur Erlangung des Doktorgrades der Medizin des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität Frankfurt am Main vorgelegt von Stefan Prgomet, dr. med. aus Düsseldorf Frankfurt am Main, 2019 1 Dekan: Prof. Dr. Stefan Zeuzem Referent/in: Prof. Dr. Ivan Dikic Korreferent/in: Prof. Dr. Jörg Trojan Tag der mündlichen Prüfung: 12.05.2020 2 Contents 1 Summary / Zusammenfassung .................................................................... 6 / 8 2 Introduction ...................................................................................................... 10 2.1 SPRTN regulates a progeria and tumorigenesis axis ............................ 10 2.1.1 RJALS-syndrome as the clinical manifestation of SPRTN malfunction 10 2.1.2 SPRTN acts in DNA damage repair ..................................................... 11 2.1.3 SPRTN’s essential function remains unknown ..................................... 13 2.2 DNA damage response (DDR) .................................................................. 16 2.2.1 Types of DNA-lesions ........................................................................... 16 2.2.2 DNA damage repair mechanisms ......................................................... 18 2.2.3
    [Show full text]
  • Sex-Specific Effects of Cytotoxic Chemotherapy Agents
    www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment.
    [Show full text]
  • Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
    Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI.
    [Show full text]
  • For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline
    ANTICANCER RESEARCH 36: 419-426 (2016) Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline KATRIN ALMSTEDT1, PETER A. FASCHING1, ANTON SCHARL2, CLAUDIA RAUH1, BRIGITTE RACK3, ALEXANDER HEIN1, CAROLIN C. HACK1, CHRISTIAN M. BAYER1, SEBASTIAN M. JUD1, MICHAEL G. SCHRAUDER1, MATTHIAS W. BECKMANN1 and MICHAEL P. LUX1 1Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany; 2Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany; 3Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany Abstract. Background/Aim: The aim of this single-arm, (MBC) is still a challenge. The majority of patients with prospective, multicenter phase II trial (MiX) was to increase breast cancer receive an anthracycline-based regimen as first treatment options for women with metastatic breast cancer chemotherapy, in an adjuvant, neoadjuvant, or metastatic pretreated with anthracycline and taxane by evaluation of the setting. The development of drug resistance and impairment efficacy and toxicity of the combination of mitomycin C and of organ functions limits the choice of further cytotoxic capecitabine. Patients and Methods: From 03/2004 to drugs in the metastatic situation. Although many patients are 06/2007, a total of 39 patients were recruited and received willing to receive further anticancer therapy to counteract mitomycin C in combination with capecitabine. The primary tumor growth, they often request a less toxic but still end-point was to determinate the tumor response according effective therapy. At present taxanes (e.g. paclitaxel, to Response Evaluation Criteria in Solid Tumors and the rate docetaxel, nab-paclitaxel), eribulin, vinorelbine, 5- of toxicities (safety).
    [Show full text]
  • Chemotherapy and Drug Resistance
    Chemotherapy and Drug Resistance Prof. Ramesh Chandra Department of Chemistry University of Delhi The thought of having chemotherapy frightens many people. Almost everyone has heard stories about someone who was "on chemo." But we believe that knowing what chemotherapy is, how it works, and what to expect can often help calm your fears and give you more of a sense of control. Chemotherapy and Drug Resistance • History • Principles • Side effects • Categories of chemotherapeutics • Drug resistance What is chemotherapy? History: Started after World War II (mustard gas) 1950's-1970's e.g., lymphoma/ALL, germ cell tumors >>> effective solid tumors (>90%) >>> resistant 1970's- research on drug resistance palliative >>> aggressive (control, cure) e.g., pre- and post-treatment of breast cancer surgery combination with radiotherapy of osteosarcoma • Why chemotherapy is different from other treatments? (systematic) • Chemotherapy in clinical trials (depending on drugs) Cancer response to anticancer drugs High responsiveness: HLL, lymphoma Partial responsiveness: breast and ovarian cancer Poor responsiveness: melanoma, small cell lung cancer “Heterogeneous drug sensitivity“ in same type of cancers Chemotherapy and Drug Resistance • History • Principles • Side effects • Categories of chemotherapeutics • Drug resistance How does chemotherapy work? Proliferating cells M G1 Growth arrest G 2 Differentiation Apoptosis S Cell Cycle Phases G1 phase. Metabolic changes prepare the 18_02_four_phases.jpg Premitotic synth of cell for division. At a certain point - the structures, mol’s restriction point - the cell is committed to division and moves into the S phase. thesisS phase replicates. DNA the synthesisgenetic material.replicates Each thechromosome now consists of two sister chromatids.genetic material. Each chromosome now G2consists phase.ofMetabolictwo sister changeschromatids assemble.
    [Show full text]
  • Recent Advances in the Management of Hormone Refractory Prostate Cancer
    Korean J Uro-Oncol 2004;2(3):147-153 Recent Advances in the Management of Hormone Refractory Prostate Cancer Mari Nakabayashi, William K. Oh Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA A typical treatment strategy after AAWD is to use secondary INTRODUCTION hormonal manipulations, although studies have not yet demonstrated a survival benefit with this class of treatment. Prostate cancer is the most common cancer in men in the Options in this category include (1) the secondary use of anti- United States and accounted for 29,900 deaths in 2003.1 androgens (e.g., high-dose bicalutamide, nilutamide), (2) thera- Although most men with advanced prostate cancer respond pies targeted against adrenal steroid synthesis (e.g., ketocona- initially to androgen deprivation therapies (ADT) by either zole, corticosteroids), and (3) estrogenic therapies (e.g. diethy- bilateral orchiectomy or leuteinizing hormone releasing hor- lstilbestrol). Symptomatic improvement and PSA responses mone (LHRH) analogues, patients eventually progress to an (defined as PSA decline >50% after treatment) have been androgen-independent state in which the initial ADT no longer reported in approximately 20% to 80% of patients with is adequate to control disease.2 Progression of the disease hormone-refractory prostate cancer (HRPC) with a typical manifests as an increase in serum prostate-specific antigen duration of response of 2 to 6 months. Toxicity is generally (PSA) or may be accompanied by radiographic evidence of mild for these oral therapies, although serious side effects, tumor growth. Here we report a brief summary of recent including adrenal insufficiency, liver toxicity, and thrombosis, advances in the management of hormone refractory prostate may occur (Table 1).
    [Show full text]
  • Multiplexed Small Molecule Ligand Binding Assays by Affinity Labeling and DNA Sequence Analysis
    Multiplexed Small Molecule Ligand Binding Assays by Affinity Labeling and DNA Sequence Analysis Bo Cai and Casey J. Krusemark* Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States Abstract: Small molecule binding assays to target proteins are a core component of drug discovery and development. While a number of assay formats are available, significant drawbacks still remain in cost, sensitivity, and throughput. To improve assays by capitalizing on the power of DNA sequence analysis, we have developed an assay method that combines DNA encoding with split-and-pool sample handling. The approach involves affinity labeling of DNA-linked ligands to a protein target. Critically, the labeling event assesses ligand binding and enables subsequent pooling of several samples. Application of a purifying selection on the pool for protein-labeled DNAs allows detection of ligand binding by quantification of DNA barcodes. We demonstrate the approach in both ligand displacement and direct binding formats and demonstrate its utility in determination of relative ligand affinity, profiling ligand specificity, and high-throughput small molecule screening. The identification and characterization of small molecule ligands to proteins are central to the development of drugs and chemical probes.1-4 While a variety of assay approaches are available for detecting protein-ligand interactions,5-7 significant limitations exist, particularly in the areas of throughput,
    [Show full text]